OncoDaily
banner
oncodaily.bsky.social
OncoDaily
@oncodaily.bsky.social
Your daily dose of hope, inspiration, and information in the fight against cancer.
oncodaily.com
ASCENT-04/KEYNOTE-D19 Trial: First-Line Sacituzumab Govitecan Plus Pembrolizumab Improves Outcomes in PD-L1–Positive Metastatic Triple-Negative Breast Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer
ASCENT-04/KEYNOTE-D19 Trial: First-Line Sacituzumab Govitecan Plus Pembrolizumab Improves Outcomes in PD-L1–Positive Metastatic Triple-Negative Breast Cancer - OncoDaily
The phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrates that first-line sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival and response durability versus chemothera...
oncodaily.com
January 24, 2026 at 11:40 PM